Towards a blood-based diagnostic panel for bipolar disorder
Background: Bipolar disorder (BD) is a costly, devastating and life shortening mental disorder that is often misdiagnosed, especially on initial presentation. Misdiagnosis frequently results in ineffective treatment. We investigated the utility of a biomarker panel as a diagnostic test for BD. Metho...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2016
|
| In: |
Brain, behavior and immunity
Year: 2015, Volume: 52, Pages: 49-57 |
| ISSN: | 1090-2139 |
| DOI: | 10.1016/j.bbi.2015.10.001 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1016/j.bbi.2015.10.001 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0889159115300271 
|
| Author Notes: | Frieder Haenisch, Jason D. Cooper, Andreas Reif, Sarah Kittel-Schneider, Johann Steiner, F. Markus Leweke, Matthias Rothermundt, Nico J.M. van Beveren, Benedicto Crespo-Facorro, David W. Niebuhr, David N. Cowan, Natalya S. Weber, Robert H. Yolken, Brenda W.J.H. Penninx, Sabine Bahn |
| Summary: | Background: Bipolar disorder (BD) is a costly, devastating and life shortening mental disorder that is often misdiagnosed, especially on initial presentation. Misdiagnosis frequently results in ineffective treatment. We investigated the utility of a biomarker panel as a diagnostic test for BD. Methods and findings: We performed a meta-analysis of eight case-control studies to define a diagnostic biomarker panel for BD. After validating the panel on established BD patients, we applied it to undiagnosed BD patients. We analysed 249 BD, 122 pre-diagnostic BD, 75 pre-diagnostic schizophrenia and 90 first onset major depression disorder (MDD) patients and 371 controls. The biomarker panel was identified using ten-fold cross-validation with lasso regression applied to the 87 analytes available across the meta-analysis studies. We identified 20 protein analytes with excellent predictive performance [area under the curve (AUC)⩾0.90]. Importantly, the panel had a good predictive performance (AUC 0.84) to differentiate 12 misdiagnosed BD patients from 90 first onset MDD patients, and a fair to good predictive performance (AUC 0.79) to differentiate between 110 pre-diagnostic BD patients and 184 controls. We also demonstrated the disease specificity of the panel. Conclusions: An early and accurate diagnosis has the potential to delay or even prevent the onset of BD. This study demonstrates the potential utility of a biomarker panel as a diagnostic test for BD. |
|---|---|
| Item Description: | Gesehen am 28.01.2019 Available online 13 October 2015 |
| Physical Description: | Online Resource |
| ISSN: | 1090-2139 |
| DOI: | 10.1016/j.bbi.2015.10.001 |